RARE
Ultragenyx Pharmaceutical Inc.
Key Financials
Operating Income
$-535000000
↑ 0.2%
Revenue
$673.0M
↑ 20.1%
Net Income
$-575000000
↓ 1.0%
EPS (Diluted)
$-5.83
↑ 7.3%
Total Assets
$1.5B
↑ 1.9%
Shareholders' Equity
$-80000000.00
↓ 131.3%
Total Liabilities
$1.6B
↑ 29.3%
Cash & Equivalents
$421.0M
↑ 142.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 7/1/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 144 | 6/15/2026 | View on SEC |
| 144 | 6/15/2026 | View on SEC |
| S-8 | 6/12/2026 | View on SEC |
| 4 | 6/1/2026 | View on SEC |
| 144 | 6/1/2026 | View on SEC |
| 4 | 5/18/2026 | View on SEC |
| 4 | 5/18/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RARE |
| Company Name | Ultragenyx Pharmaceutical Inc. |
| CIK | 1515673 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 415-483-8800 |